RVL Pharmaceuticals announced that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride ophthalmic solution, 0.1%) was selected as the "Best Professional Treatment Product” in the Shape Healthy Beauty Awards, the annual awards conducted by Shape magazine.

According to Shape, the products selected are tested over the course of a year and determined to be the most impressive new innovations, treatment trends, and what top-tier professionals turn to for patient solutions. Elizabeth Hale, MD, a board-certified dermatologist in New York City, refers to the active ingredient in Upneeq as a "trigger” for the contraction of an involuntary muscle called the Müller's muscle to lift the drooping eyelid. 

“As we continue to grow and make our mark in the medical aesthetics field we are thrilled to be once again acknowledged by an industry leader like Shape,” said JD Schaub, executive vice president & COO of RVL Pharmaceuticals. “Another accolade elevates the Upneeq brand and we hope furthers the vote of confidence hundreds of medical aesthetics offices have in our treatment for this unmet need in acquired ptosis therapy.”

Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%) received FDA approval in July 2020, introducing to the market the only nonsurgical therapeutic approved for treating acquired blepharoptosis in adults. Upneeq is a safe and effective, first-in-class treatment providing eye care and medical aesthetic providers a simple convenient daily drop. In clinical trials, Upneeq demonstrated statistically significant improvements compared to vehicles in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy and safety studies.